文献速递骨软组织肉瘤与黑色素瘤

伊匹木单抗治疗存在NY-ESO-1体液免疫应答的黑色素瘤患者II期试验

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
PubMed 文献 · Eur J Cancer · 2018-01-05

主要终点irRC疾病控制率为52%,irPR为36%,中位OS为22.7个月,1年生存率66.8%。NY-ESO-1特异性免疫应答与临床活性未见明确关联。

要点

  • 伊匹木单抗在NY-ESO-1体液免疫应答黑色素瘤患者中irRC疾病控制率达52%
  • 中位OS为22.7个月,1年生存率66.8%,治疗相关3级不良事件发生率36%
  • NY-ESO-1特异性细胞或体液免疫应答与临床活性未见明确关联

核心结论

  • 伊匹木单抗在NY-ESO-1体液免疫应答定义的黑色素瘤人群中显示出临床相关活性。
  • NY-ESO-1阳性作为既存抗肿瘤免疫应答的替代标志,可能有助于识别从免疫检查点阻断中获益更优的患者。

研究设计与样本

  • 伊匹木单抗剂量为10 mg/kg,第1、4、7、10周给药,随后每3个月维持治疗,最长48周。
  • 主要终点为按免疫相关疗效标准(irRC)评估的疾病控制率(irCR、irPR或irSD)。
  • 次要终点包括按RECIST标准评估的疾病控制率、无进展生存期和总生存期(OS),并分析血样本中针对NY-ESO-1的体液和细胞免疫应答。

主要发现

  • 按irRC评估的疾病控制率为52%,irPR见于36%的患者。
  • 按irRC评估的中位无进展生存期为7.8个月,按RECIST标准评估为2.9个月。
  • 中位OS为22.7个月,相应1年生存率为66.8%。
  • 治疗相关3级不良事件发生率为36%,未发生4-5级不良事件。
  • NY-ESO-1特异性细胞或体液免疫应答的存在与临床活性之间未发现明确关联。

关键数值与推荐

  • 主要终点疾病控制率按irRC评估为52%,irPR为36%。
  • 中位无进展生存期按irRC为7.8个月,按RECIST为2.9个月。
  • 中位OS为22.7个月,1年生存率为66.8%。
  • 治疗相关3级不良事件发生率为36%,无4-5级不良事件。

临床怎么用

  • 在存在NY-ESO-1体液免疫应答的转移性黑色素瘤患者中,伊匹木单抗10 mg/kg方案显示出临床相关活性。
  • NY-ESO-1阳性可能作为既存抗肿瘤免疫应答的替代标志,辅助识别可能从免疫检查点阻断中获益更优的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity. PATIENTS AND METHODS: Twenty-five patients with previously untreated or treated metastatic melanoma and preexisting humoural immune response against NY-ESO-1 received ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks. Primary endpoint was the disease control rate (irCR, irPR or irSD) according to immune-related response criteria (irRC). Secondary endpoints included the disease control rate according to RECIST criteria, progression-free survival and overall survival (OS). Humoural and cellular immune responses against NY-ESO-1 were analysed from blood samples. RESULTS: Disease control rate according to irRC was 52%, irPR was observed in 36% of patients. Progression-free survival according to irRC was 7.8 months, according to RECIST criteria it was 2.9 months. Median OS was 22.7 months; the corresponding 1-year survival rate was 66.8%. Treatment-related grade 3 AEs occurred in 36% with no grade 4-5 AEs. No clear association was found between the presence of NY-ESO-1-specific cellular or humoural immune responses and clinical activity. CONCLUSION: Ipilimumab demonstrated clinically relevant activity within this biomarker-defined population. NY-ESO-1 positivity, as a surrogate for a preexisting immune response against tumour antigens, might help identifying patients with a superior outcome from immune checkpoint blockade. CLINICAL TRIAL INFORMATION: NCT01216696.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Haag GM, Zoernig I, Hassel JC, et al. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Eur J Cancer. 2018. PMID: 29306769. doi:10.1016/j.ejca.2017.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。